Sorry Rappers, page-114

"To top it all off we have found out Australian clinical trials have not been running to even the TGA's standard."

I think you're being very unfair with this comment. The Australian study was never a trial, and never purported to be one. Resapp has been completely open with the purpose of the study, which was to obtain training data and test the predictive capability of the algorithm once trained. Ditto for the Indonesian study.

If Resapp had conducted the trial here first with positive results, you'd be slamming the management for conducting the trials here where the population (and hence revenue base) of the entire country amounts to a single state in the USA.

You seem to be making investment decisions with your emotions. Sell at the best exit point you can see in the short term, and put your money where it will work for you. But I think that by writing off the product as well as the trial, you're boiling the baby in the bathwater!